Financials Cerevel Therapeutics Holdings, Inc.

Equities

CERE

US15678U1280

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-19 pm EDT 5-day change 1st Jan Change
42.21 USD +0.17% Intraday chart for Cerevel Therapeutics Holdings, Inc. +0.86% -0.45%

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 2,108 4,773 4,928 7,659 7,664 - -
Enterprise Value (EV) 1 1,724 4,208 4,313 6,820 6,955 6,974 7,664
P/E ratio -8.25 x -19.6 x -13.6 x -15.9 x -16.9 x -15 x -15.3 x
Yield - - - - - - -
Capitalization / Revenue - - - - - - 95.1 x
EV / Revenue - - - - - - 95.1 x
EV / EBITDA -11.6 x -19.4 x -11.9 x -15.4 x -15 x -12.5 x -14.1 x
EV / FCF -12.6 x -22.3 x -14.5 x -19.7 x -23.4 x -14.1 x -17.1 x
FCF Yield -7.93% -4.49% -6.89% -5.07% -4.27% -7.11% -5.85%
Price to Book - 8.28 x 9.47 x - - - -
Nbr of stocks (in thousands) 127,124 147,236 156,244 180,634 181,576 - -
Reference price 2 16.58 32.42 31.54 42.40 42.21 42.21 42.21
Announcement Date 3/24/21 3/1/22 2/22/23 2/27/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - - 80.58
EBITDA 1 -148.7 -217.4 -362.9 -441.6 -462.2 -556.9 -544.2
EBIT 1 -149.1 -220.1 -367.8 -447.3 -486.8 -546 -534.2
Operating Margin - - - - - - -662.97%
Earnings before Tax (EBT) 1 -152.2 -225.3 -351.4 -432.3 -447.7 -547.5 -564.9
Net income 1 -152.1 -225.3 -351.5 -432.8 -455.7 -550.9 -570.1
Net margin - - - - - - -707.51%
EPS 2 -2.010 -1.650 -2.320 -2.670 -2.493 -2.813 -2.750
Free Cash Flow 1 -136.7 -189 -297.1 -346.1 -296.7 -495.7 -448.3
FCF margin - - - - - - -556.34%
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share 2 - - - - - - -
Announcement Date 3/24/21 3/1/22 2/22/23 2/27/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 - - - - - - - - - - - - - - -
EBITDA - - - - -93.8 -106 - - -109.9 -138.1 - - - - -
EBIT 1 -54.53 -64.49 -72.53 -93.01 -95.06 -107.2 -99.55 -96.84 -111.3 -139.6 -119.4 -120.4 -122.8 -126.9 -125
Operating Margin - - - - - - - - - - - - - - -
Earnings before Tax (EBT) 1 -62.06 -59.06 -68.29 -90.47 -99.94 -92.65 -104.2 -99.43 -96.24 -132.5 -110.2 -108.6 -113.3 -114.7 -123
Net income 1 -62.06 -59.06 -68.29 -90.47 -99.94 -92.81 -104.3 -99.54 -96.36 -132.7 -110.2 -108.6 -113.3 -114.7 -123
Net margin - - - - - - - - - - - - - - -
EPS 2 -0.4300 -0.4000 -0.4600 -0.6100 -0.6600 -0.5900 -0.6700 -0.6300 -0.6100 -0.7600 -0.6114 -0.5971 -0.6314 -0.6157 -0.7200
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/10/21 3/1/22 5/10/22 8/1/22 11/8/22 2/22/23 5/3/23 8/2/23 11/1/23 2/27/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - -
Net Cash position 1 384 566 615 839 709 690 -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 1 -137 -189 -297 -346 -297 -496 -448
ROE (net income / shareholders' equity) - -46.8% -63.9% -72.4% -64.7% -69.1% -
ROA (Net income/ Total Assets) - -39.7% -41.2% -38.3% -35.4% -38.3% -
Assets 1 - 567.1 853.4 1,131 1,287 1,439 -
Book Value Per Share - 3.920 3.330 - - - -
Cash Flow per Share 2 - - - -2.110 -2.300 - -
Capex 1 18.9 10.5 3.95 3.81 9.41 9.89 8.75
Capex / Sales - - - - - - 10.86%
Announcement Date 3/24/21 3/1/22 2/22/23 2/27/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
42.21 USD
Average target price
44.78 USD
Spread / Average Target
+6.08%
Consensus
  1. Stock Market
  2. Equities
  3. CERE Stock
  4. Financials Cerevel Therapeutics Holdings, Inc.